Upgrade to SI Premium - Free Trial

Acadia Pharmaceuticals (ACAD) Stock Selloff Is Over Done Says UBS, 'the level of sell-off is surprising to us'

March 12, 2024 4:07 PM
UBS analyst Ashwani Verma lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $35.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles